BOT 1.43% 34.5¢ botanix pharmaceuticals ltd

New Hartley Analyst report on Bot, page-63

  1. 157 Posts.
    lightbulb Created with Sketch. 64
    Going back to ol' mate LDX and its blindsided approval in July this year, maybe there is an opportunity for a quicker submission and/or approval. I realise that LDX's was a medical device and the rejection might've been Cat 1 but their investor presentation said in March this year :
    "Following presub meeting, planning to file second 510(k) with FDA during CY2023"
    .
    4 months later they get approval with not a word announced to the market beforehand.
    Sorry to include this in the BOT thread but Howie's 3-6 months could have some merit. As with LDX, a lot can happen in the background that we don't hear about.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.